{"type":"trials","record":{"id":28310,"source_id":"clinicaltrials-gov","external_id":"NCT07440225","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","brief_summary":"Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.","overall_status":"Recruiting","phases":["PHASE2","PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"EyeBiotech Ltd.","enrollment":960,"countries":["United States","Argentina","Australia","Estonia","Germany","Israel","Latvia","Poland","Puerto Rico","Spain","Switzerland","United Kingdom"],"start_date":"2026-03-27","completion_date":"2028-06-30","last_update_date":"2026-09-18","source_url":"https://clinicaltrials.gov/study/NCT07440225","editorial_summary":"A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"MALBEC","age_range":"50 Years","comparator":"Aflibercept 2 mg","organization":"EyeBiotech Ltd.","interventions":["Tiespectus","Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean Change in Best-Corrected Visual Acuity (BCVA) [Early Treatment of Diabetic Retinopathy Study (ETDRS Letters)] From…","Mean Change in BCVA (ETDRS Letters) From Baseline (Day 1) Over Time to Year 1 — Up to Year 1","Proportion of Participants Who Gain ≥5 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Gain ≥10 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Gain ≥15 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Lose ≥5 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Lose ≥10 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Lose ≥15 ETDRS Letters at Year 1 — Year 1","Mean Change in Spectral Domain Optical Coherence Tomography (SD-OCT) Central Subfield Thickness (CST) From Baseline (Da…","Number of Participants who Experience One or More Systemic Adverse Events (AEs) — Up to approximately 96 weeks","Number of Participants who Experience One or More Ocular AEs — Up to approximately 96 weeks"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Macular Degeneration","Age-Related Macular Degeneration","Choroidal Neovascularization","Wet Macular Degeneration","Tiespectus","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07440225","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-03-27 to 2028-06-30","comparator":"Aflibercept 2 mg","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.793Z","intervention":["Tiespectus","Aflibercept"],"participants":960,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2, PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean Change in Best-Corrected Visual Acuity (BCVA) [Early Treatment of Diabetic Retinopathy Study (ETDRS Letters)] From…","Mean Change in BCVA (ETDRS Letters) From Baseline (Day 1) Over Time to Year 1 — Up to Year 1","Proportion of Participants Who Gain ≥5 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Gain ≥10 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Gain ≥15 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Lose ≥5 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Lose ≥10 ETDRS Letters at Year 1 — Year 1","Proportion of Participants Who Lose ≥15 ETDRS Letters at Year 1 — Year 1","Mean Change in Spectral Domain Optical Coherence Tomography (SD-OCT) Central Subfield Thickness (CST) From Baseline (Da…","Number of Participants who Experience One or More Systemic Adverse Events (AEs) — Up to approximately 96 weeks","Number of Participants who Experience One or More Ocular AEs — Up to approximately 96 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28310","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}